Roche bets $545M on Trophos’ once-failed orphan drug

Damian Garde Roche has signed a deal to trade up to €470 million ($ 545 million) for Trophos, a company at work on a mid-stage treatment for the rare and debilitating spinal muscular ...

Singapore to detail trial of MicroVAX novel cancer vaccine

EJ Lane The National Cancer Centre of Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration ...

Orphazyme hauls in $24M to advance its rare disease contender

Damian Garde Danish biotech Orphazyme raised a €20 million ($ 24 million) B round to fund its work on rare lysosomal storage disorders, tapping an investor syndicate that includes ...

Daiichi’s Savaysa goes up against next-gen anticoagulant trio in heated market race

Carly Helfand What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday ...

Daiichi Sankyo to pay $39M to settle DOJ claims it paid kickbacks to docs

Eric Palmer Japanese drugmaker Daiichi Sankyo will pay the $ 39 million to the state and federal health programs, and a whislteblower, to settle claims it paid doctors kickbacks to ...

Euro VC Fountain unveils a $101M biotech fund

Damian Garde Fountain Healthcare Partners put together an €85 million ($ 101 million) new purse, money the Irish investor plans to pour into biotech startups. FierceBiotech News

Hedge fund exec aims new legal weapon at Big Pharma’s ‘evergreened’ patents

Emily Wasserman As companies, regulators and advocacy groups lobby to bring certain branded products off-patent, a new voice is joining the chorus. U.S. hedge fund manager Kyle Bass, ...

AbbVie, Neurocrine report a PhIII win for blockbuster contender elagolix

John Carroll AbbVie investigators delivered a fresh set up promising results for a key late-stage drug in the pipeline. In the first of two Phase III studies, the company reports that ...

Vertex gets 500-patient boost with FDA’s newest Kalydeco nod

Carly Helfand Vertex will start the new year with a group of new eligible patients for cystic fibrosis drug Kalydeco, thanks to a Monday green light from the FDA. The agency has OK'd ...

Biopharma posts a chart-topping 41 new drug approvals in 2014

Alok Saboo FierceBiotech News

Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit’s spinoff

Carly Helfand It's new year, new company for Reckitt Benckiser's pharma unit, spun off into Indivior last week. And while 2015 might not be the easiest for the newly minted ...

With Roche out the door, Chiasma is raising $56M to go it alone

Damian Garde In early 2013, Roche signed a $ 595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker ...
Page 2 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS